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Vertebroplasty and Kyphoplasty: A Systematic Review
of 69 Clinical Studies
Paul A. Hulme, MSc,* Jo¨rg Krebs, DVM,* Stephen J. Ferguson, PhD,* and
Ulrich Berlemann, MD†
Study Design. Systematic literature review.
Objective. To evaluate the safety and efficacy of ver-
tebroplasty and kyphoplasty using the data presented in
published clinical studies, with respect to patient pain
relief, restoration of mobility and vertebral body height,
complication rate, and incidence of new adjacent verte-
bral fractures.
Summary of Background Data. Vertebroplasty and ky-
phoplasty have been gaining popularity for treating ver-
tebral fractures. Current reviews provide an overview of
the procedures but are not comprehensive and tend to
rely heavily on personal experience. This article aimed to
compile all available data and evaluate the clinical out-
come of the 2 procedures.
Methods. This is a systematic review of all the avail-
able data presented in peer-reviewed published clinical
trials. The methodological quality of included studies was
evaluated, and data were collected targeting specific stan-
dard measurements. Where possible, a quantitative ag-
gregation of the data was performed.
Results. A large proportion of subjects had some pain
relief, including 87% with vertebroplasty and 92% with
kyphoplasty. Vertebral height restoration was possible
using kyphoplasty (average 6.6°) and for a subset of pa-
tients using vertebroplasty (average 6.6°). Cement leaks
occurred for 41% and 9% of treated vertebrae for verte-
broplasty and kyphoplasty, respectively. New fractures of
adjacent vertebrae occurred for both procedures at rates
that are higher than the general osteoporotic population
but approximately equivalent to the general osteoporotic
population that had a previous vertebral fracture.
Conclusions. The problem with stating definitely that
vertebroplasty and kyphoplasty are safe and effective pro-
cedures is the lack of comparative, blinded, randomized
clinical trials. Standardized evaluative methods should be
adopted.
Key words: osteoporotic, vertebral fracture, vertebro-
plasty, kyphoplasty. Spine 2006;31:1983–2001
Osteoporosis is estimated to afflict 200 million women
worldwide.1 A total of 1.5 million new fractures, nearly
half of which are vertebral (700,000), are reported in the
United States each year, outnumbering fractures of the
hip and ankle combined.2–5 Vertebral fracture may result
in pain about the fracture site, loss of height caused by
vertebral collapse, spinal instability, and, in many cases,
kyphotic deformity.6 Although some patients respond to
the conservative treatment of medications, bracing, and
bed rest, many do not. Chronic pain and kyphotic defor-
mity may lead to depression, decreased appetite (leading
to poor nutrition), decreased pulmonary function, im-
paired mobility, and a reduction in the quality of life, the
ultimate result being a significant increase in morbid-
ity.7–11 To relieve chronic pain, bed rest is often the only
solution. However, this solution can result in a vicious
cycle of increased bone loss caused by inactivity and,
correspondingly, increased vertebral fracture risk.8
Thus, interest has been fostered in percutaneous cement
injection methods for fracture stabilization that reduce
or eliminate pain, allowing a return to normal activity in
a short period of time.
Galibert et al12 first reported vertebroplasty in 1987 for
the minimally invasive treatment of hemangiomas, which,
since then, has been adapted for use in the treatment of
intractable, focal, intense pain localized to a vertebral frac-
ture. Kyphoplasty was introduced in 1998 to restore verte-
bral body height and help realign the spine, using an inflat-
able balloon to reduce the fracture before the injection of
cement.8,13 Currently, vertebroplasty and kyphoplasty
have been gaining popularity to stabilize vertebral fractures
mainly caused by osteoporosis but also including malignant
involvement of the spinal column, hemangioma, and verte-
bral osteonecrosis.14 There is a need for critical evaluation
of the supporting evidence to provide, where possible, a
quantitative aggregation of the safety and efficacy of the
procedures. A number of reviews of the 2 procedures cur-
rently exist.3,13,15–21 Although they provide an excellent
overview of the procedures, they are not comprehensive
and tend to rely heavily on personal experience rather than
objective assessment. This article will compile the available
data presented in peer-reviewed published clinical studies
to address the following questions:
1. Does vertebroplasty/kyphoplasty reduce patient
pain? How does this compare to conservative
treatment? Is pain reduction durable over the long-
term?
2. Does vertebroplasty/kyphoplasty restore patient
function?
3. Does vertebroplasty/kyphoplasty restore the nor-
mal spinal alignment?
From the *M.E. Mu¨ller Institute for Surgical Technology and Biome-
chanics, Bern, and †Spine Center, Thun, Switzerland.
Acknowledgment date: February 16, 2005. First revision date: July 15,
2005. Second revision date: October 14, 2005. Acceptance date: Oc-
tober 19, 2005.
The device(s)/drug(s) is/are FDA-approved or approved by correspond-
ing national agency for this indication.
Foundation funds were received in support of this work. No benefits in
any form have been or will be received from a commercial party related
directly or indirectly to the subject of this manuscript.
Address correspondence and reprint requests to Paul A. Hulme, MSc,
Research Center for Orthopaedic Surgery, Institute for Surgical Tech-
nology and Biomechanics, University of Bern, Stauffacherstr. 78, 3014
Bern, Switzerland; E-mail: Paul.Hulme@MEMcenter.unibe.ch
1983
4. What are the complications associated with the
procedures?
5. Does the incidence of augmented oradjacentvertebral
fracture increase after vertebroplasty/kyphoplasty?
6. Does kyphoplasty offer a significant improvement in
terms of restoration of spinal alignment, pain man-
agement, and reduction in cement leakage over tra-
ditional vertebroplasty?
Materials and Methods
To our knowledge, there are no published reports of random-
ized clinical trials for either vertebroplasty or kyphoplasty,
therefore, the search was extended to include nonrandomized
clinical trials.22 No restrictions were placed on the age or gen-
der of the subjects, or the duration, localization, and type of
symptoms experienced.
Search Strategy. MEDLINE, Cochrane Library, and ISI Cur-
rent Contents were searched. No restrictions were placed on
language, publication date, or publication type for the initial
searches within these databases. Searches were performed in
June and November 2004 and repeated in June 2005. For the
initial search, the terms “vertebroplasty” and “kyphoplasty”
were used because they have been established terms from the
inception of the techniques. Specific key words were used to
focus the search results on clinical studies, further refined by
manual inspection of the abstracts. Articles were excluded
from further analysis for reporting no clinical outcomes (i.e.,
article was a review, editorial, technical, or animal study), in-
volving techniques other than vertebroplasty/kyphoplasty, or if
the study was published in a language other than English, Ger-
man, French, or Spanish. To reduce potential confounding fac-
tors, included studies were limited to subject populations that
had more than 80% primary or secondary osteoporotic verte-
bral compression fractures and procedures that used polym-
ethyl methacrylate cement. We tested our search strategy by
ensuring that our search results included all the studies identi-
fied by previous reviews.3,13,20,23
Methodological Evaluation. To date, a standardized
method for the evaluation of nonrandomized studies has not
been formalized. We used a modified version of the method-
ological quality assessment proposed by Downs and Black24
and later modified by MacLehose et al,25 and included recom-
mendations of other investigators (Table 1).26,31 It contains all
the elements recommended by the Agency for Healthcare Re-
search and Quality, Cochrane Collaboration Back Review
Group, NSW Department of Health, NHS R&D Health Tech-
nology Assessment Programme, and the Ottawa Health Re-
search Institute.28,30–32 Questions were grouped into the cate-
gories: reporting; external validity; internal validity, including
bias and confounding; and power (Table 1). Internal validity
refers to systematic errors of biases or confounding factors
inherent in the study design. External validity refers to how the
results provide a correct basis for generalization to other cir-
cumstances.33 At least 2 reviewers reviewed articles. Reviewers
gave each element a score of 1 (yes) or 0 (no, unclear). We
aimed for consensus, but if necessary, a third reviewer was
consulted.
DataCollection.Data were collected for each study under the
headings “general information,” “participants,” “interven-
tion,” “outcomes,” “complications,” and “follow-up.” Gen-
eral information included the type of intervention, pathology,
and type of study. Participant information was comprised of
the age and gender of the subjects, description of symptoms,
and drop out during follow-up. Cement type, injected
amounts, approach, number of sessions, number of vertebra
per session, levels augmented, usage of fluoroscopy, computer-
ized tomography (CT), and venography were all noted under
the heading “intervention.” Outcome data were collected de-
tailing pain relief, general health, functional improvements,
satisfaction with treatment, and reduction in kyphosis. Com-
plications included cement leakage (asymptomatic and symp-
tomatic), neurologic deficits, cardiovascular, pulmonary, and
any other clinically relevant complication. Long-term fol-
low-up information was comprised of all the items recorded
under the heading “outcome,” with the addition of new frac-
ture details. It is noteworthy that studies that did not explicitly
state whether cement leakage, complications, or new fractures
did or did not occur were not included in totals used to calcu-
late the proportion of subjects/vertebrae that were affected.
Statistics. Statistics were kept to a descriptive level. Compar-
ative data (i.e., differences in VAS) are reported as the difference
between the means95% confidence level calculated from the
standard error of the difference between 2 sample means. Bi-
nomial proportional data are expressed as the proportion 
95% confidence level calculated from the standard error using
the normal approximation. The combined mean across multi-
ple studies was weighted according to the number of subjects
and is expressed as the combined mean  the combined 95%
confidence level (calculated from the within study variance).
Results
Methodological Analysis
The majority of articles reviewed were retrospective in
nature, including 37 retrospective, 25 prospective, and 7
study design not reported. The evaluated articles were of
varying methodological quality. Mean quality score was
17.6  3.7 standard deviation (SD) (range 9–23.5) of a
maximum of 29. The summary of the methodological
score for each question is provided in Figure 1. Although
descriptive parameters were often reported (question
Nos. 1–4, and 9), no study was randomized, and only a
few studies had an aspect of the study that was blinded
(question Nos. 16 and 26).34–39 While not specifically
targeted in the methodological quality assessment, it was
noted that very few studies included a control group.40,41
Items that were not consistently reported were con-
founding factors, bias and limitations (question Nos. 5,
7, 24, and 27).
On the whole, the main findings were not clearly de-
scribed (question No. 4), and results were presented with-
out information on their variability (question No. 8). Fol-
low-up times were assessed with respect to the aim of the
study. Remarkably, those studies whose aims were to assess
the pain relief and occurrence of new fractures after verte-
broplasty and kyphoplasty often had short or no follow-up
times (question No. 19). No studies were excluded on the
basis of methodological quality because removing articles
that scored in the bottom 50% had little effect on outcomes.
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Clinical Details
Studies providing the data for this review are referenced in
Table 2. Vertebroplasty studies (12 prospective, 29 retro-
spective, and 6 unreported) showed the results of 2958 sub-
jects (n  47 studies), including 1959 females, 676 males,
and 323 unreported with a mean age of 72 years (mean
range 59–79, n  45 studies), who underwent 4456 pro-
cedures. Kyphoplasty studies (13 prospective, 8 retrospec-
tive, and 1 unreported) showed the results of 1288 subjects
(n 22 studies), including 829 females, 403 males, and 56
unreported with a mean age of 72 years (mean range 67.5–
75, n  20 studies), who underwent 1624 procedures. Of
vertebroplasty and kyphoplasty procedures, 50% and
60%, respectively, were performed within the thoracolum-
bar region of the spine (T11–L2 inclusive).
Pain
As shown in Figure 2, a large proportion of subjects had
some pain relief independent of the type of procedure:
vertebroplasty 87% (n  1552, 32 studies, 95% confi-
dence interval [CI] 78% to 95%); and kyphoplasty 92%
(n 447, 7 studies, 95% CI 86% to 98%). Visual analog
pain scores (VAS) (normalized to 10-point scale) were
reduced from an average of 8.2 (n  666, 12 studies,
95% CI 7.8–8.6) and 7.15 (n  183, 4 studies, 95% CI
6.6–7.7) to 3.0 (95% CI 2.4–3.6) and 3.4 (95% CI 2.7–
4.1) for vertebroplasty and kyphoplasty, respectively
(Figure 3). There were 2 studies that showed SF-36
scores for kyphoplasty.8,97 Body pain scores increased
between 22.4 and 47.1 points, while the physical func-
tion scores decreased between 17.2 and 29.3 points. The
only items that did not have any statistically significant
improvement were general health, role emotional, and
mental health.
Physical Function
A 16% to 47% full-scale improvement in physical func-
tion was reported after vertebroplasty for 7 studies using
different variants of a 5-point mobility scale.10,36,61–64,91
Between 49% and 90% of subjects reported ambulation
Table 1. Methodological Quality Assessment Questions
Question No. Type Methodological Question References
1 R Is the aim clearly stated and answered by the conclusion? 24–28
2 R Are the main outcomes to be measured clearly described in the introduction or methods section? 24,25
3 R Are the characteristics of the patients included in the study clearly described? 24,28
4 R Are the interventions of interest clearly described in the introduction or methods section? 24,25,28,29
5 R Are the distributions of principal confounders in each group of subjects to be compared clearly
described?
24,28
6 R Are the main findings of the study clearly described? 24,25,28
7 R Are the conclusions supported by results with biases and limitations taken into consideration? 28
8 R Does the study provide estimates of the random variability in the data for the main outcomes? 24,25,28
9 R Have all important adverse events that may be a consequence of the intervention been reported? 24,25
10 R Have the characteristics of patients lost to follow-up been described? 24,25,28
11 R Have actual probability values been reported (e.g., 0.035 rather than 0.05) for the main
outcomes except where the probability value is less than 0.001?
24,25
12 E Were the subjects asked to participate in the study representative of the entire population from
which they were recruited?
24,30
13 E Were those subjects who were prepared to participate representative of the entire population
from which they were recruited?
24
14 E Were the staff, places, and facilities where the patients were treated, representative of the
treatment the majority of patients receive?
24,25
15 I (bias) Does the study consist of consecutive patients? 26,28,29
16 I (bias) Was an attempt made to blind either the subjects to the intervention or blind those measuring the
main outcomes of the intervention?
25
17 I (bias) If any of the results of the study were based on “data dredging,” was this made clear? 24–26
18 I (bias) Are follow-up times the same for all subjects? If not, is this reported or corrected for? 24,25,28
19 I (bias) Was the follow-up appropriate for the aim of the study? 26,28–30
20 I (bias) Were the statistical tests used to assess the main outcomes appropriate? 24,25,28,29
21 I (bias) Were the main outcome measures used accurate (valid and reliable)? 24,25,28
22 I (bias) Was the funding or sponsorship independent of the intervention procedure? 28
23 I (con) Were the patients in different intervention groups (trials and cohort studies), or were the cases
and controls (case-control studies) recruited from the same population?
24
24 I (con) Were all the patients at a common point in the course of the disease to which the intervention
was to be applied?
29
25 I (con) Were study subjects in different intervention groups (trials and cohort studies), or were the cases
and controls (case-control studies) recruited over the same period of time?
24,25
26 I (con) Were study subjects randomized to intervention groups? 24,25
27 I (con) Was there adequate adjustment for confounding in the analyses from which the main findings
were drawn?
24,28
28 I (con) Were losses of patients to follow-up taken into account? 24
29 P Did the study have sufficient power to detect a clinically important effect where the probability
value for a difference being due to chance is less than 5%?
24,26,28
There were 2 questions regarding patient characteristics and randomization (question Nos. 3 and 26) subdivided because it was thought that a simple yes/no did
not allow enough flexibility, and 1 question, regarding the description of the main finding (question No. 6), was given a score between 0 and 2 because of its
perceived importance.25
E indicates external validity; I (bias), internal bias; I (con), internal confounding; P, power; R, reporting.
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improvements in 4 studies assessed by qualitative patient
response.14,34,35,65 There were 3 studies that showed im-
provements in physical function using a validated
health-related outcome instrument: Nottingham
Health Profile42,43 and Oswestry Disability Index (ODI)
(preoperative 61%, postoperative 46%, n  23 sub-
jects).44 Two kyphoplasty studies showed improvements
in disability (mean ODI preoperative 60%, postopera-
Figure 1. Methodological quality assessment score. Randomized trials were not available, and blinded trials were infrequent. The bars
represent the average score for all kyphoplasty and vertebroplasty articles reviewed.
Table 2. References for Clinical Details
Clinical Details Vertebroplasty Studies Referenced Kyphoplasty Studies Referenced
Study design
Prospective 4,14,39,40,42–50 8,41,44,51–60
Retrospective 10,17,34–38,61–82 83–90
Not Reported 91–96 97
Pain relief
Subjects with some pain relief (%) 17,34–37,42,43,46,47,49,50,61,62,65,66,68–70,72,73,75–81,91,92,94,95,98 8,41,44,51,52,55–60,83,84,87–89,97,99
Pain relief VAS 4,10,36,40,42–44,46–49,61–64,66,70,75,79,80,91,100 8,44,51–53,55,58,83,88,89,99
Mobility 10,14,34–36,43,44,48,50,61–65,73,91,101 44,51
Height restoration
Height 39,44,45,66,67,76,82,93,96 41,44,51,53,56,59,83,84,88,89,97
Correction of kyphosis 39,44,45,66,67,76,82,92,93 41,44,51–55,83,84,87
Subjects with no increase in height or
reduction in kyphosis angle (%)
39,44,45,66,67,82,92,93,96 41,44,51–53,89,97,99
Complications
Leakage 4,17,34,36,37,39,42–50,66–70,72,74–78,80,91,92,95,101,102 8,41,44,51,52,54–60,83,84,87–89,97,
Leakage location 4,14,17,34,36,37,39,42–50,66,68–70,72,74–78,80,91,92,95,101,102, 8,51,52,55,56,58,60,83,97,99
Procedural versus cement complications 4,10,14,17,34,36,37,40,42,49,50,63,68,69,70,74,75,101 8,41,51,54–57,87,88,97,
Serious complications reported 4,10,14,17,34,36,37,39,40,42–45,47–50,61,63,65–70,74–78,80,92,95,101 8,41,51,52,54–57,59,83,84,87–89,97,
New fractures 4,34,40,42,44,46–49,65,68–71,75,95,101 41,51,52,54,56–58,83–86,88
VAS indicates visual analog pain scores.
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tive 32%, n  77 subjects).44,51 Reporting improve-
ments in physical function appears to be of secondary
importance to the investigators, therefore, measurement
scales used are inconsistent, thus scores cannot be pooled.
Kyphosis/Vertebral Height Correction
A qualitative examination of the data presented in Ta-
bles 3 and 4 appears to indicate that vertebral height
restoration is similar for either procedure, provided a
mobile fracture or intravertebral cleft is present. How-
ever, few studies considered measurement precision or
corrected for magnification error between radiographs
(Tables 3, 4). Interstudy comparisons are further com-
plicated by the use of different methods for percentage
height restoration and reduction of kyphosis angle cal-
culation.45 Mean kyphotic angle restoration was 6.6°
(n  335, 4 studies, range 5.0°–8.4°)66,67,92,93 and 6.6°
(n  505, 9 studies, range 3.4°–9.9°)51,52–55,83,84,103 for
vertebroplasty and kyphoplasty, respectively. Not all
subjects had a reduction in kyphotic angle or restoration
of height (less than 5° change in kyphotic angle or an
increase in height as defined by the investigator). A mean
of 34% (n  404, 9 studies, 95% CI 22% to 46%) and
39% (n  512, 8 studies, 95% CI 28% to 50%) of
kyphoplasty and vertebroplasty interventions, respec-
tively, did not result in an appreciable restoration of
height or kyphotic angle.
Complications
Immediate complications associated with vertebroplasty
and kyphoplasty can be separated into 2 categories, pro-
cedural and cement leakage (ratio 5:14 kyphoplasty,
25:49 vertebroplasty). Reported procedural complica-
tions include infection,63,68,69 fractures of the transverse
process, pedicle, sternum and ribs,10,14,37,40,63,94,97 and
respiratory distress caused by the anesthetic.34,98 Ce-
ment leakage occurred in 41% (n  2283 vertebrae, 27
studies, 95% CI 32% to 50%) of vertebrae during ver-
tebroplasty and 9% (n  1486 vertebrae, 18 studies,
95% CI 2.6% to 15.8%) of vertebrae during kyphop-
lasty (Figure 4).
It is noteworthy that mean leakage rate was calculated
independent of the measurement method used and pa-
tient inclusion criteria. The distribution of leaks was
32% and 11% epidural, 32.5% and 48% paraspinal and
30.5% and 38% intradiscal, 1.7% and 1.5 pulmonary
and 3.3% and 1.5 foraminal for vertebroplasty (1081
leakage locations reported, 30 studies) and kyphoplasty
Figure 2. Proportion of subjects who undergo vertebroplasty and kyphoplasty, and have pain relief. Pain relief is illustrated for 4 different
methods in which it was reported. “Some pain relief” includes all patients who had a reduction in pain, regardless of the magnitude.
Studies that used the descriptor “Marked Pain Relief” did not indicate the magnitude of pain relief experienced. The other 2 methods are
self explanatory. Severe fracture is defined as a loss of vertebral height more than 67% of its original height.
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Figure 3. Funnel plots for vertebroplasty (A) and kyphoplasty (B) VAS difference scores between preoperative and postoperative values.
Variability was not provided for all studies. Therefore, 2 means were constructed, one for studies in which variability was reported and
another for all studies. The solid line indicates the region in which one would expect 95% of the data to lie within. The kyphoplasty plot
shows a symmetrical inverted funnel, indicating a probable lack of publication bias. The same is not true for the vertebroplasty plot.
Asymmetry could be caused by publication bias, inadequate methodological quality, or interstudy differences in subject inclusion criteria.
VCF indicates vertebral compression fracture.
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(65 leakage locations reported, 10 studies), respectively.
Most leaks were clinically asymptomatic. Clinical com-
plications occurred for 2.6% and 1.3% of augmented
vertebrae and 3.9% and 2.2% of subjects for vertebro-
plasty (n  2080 subjects, 3120 vertebrae, 31 studies)
and kyphoplasty (n  844 subjects, 1451 vertebrae, 17
studies), respectively. Because pulmonary emboli can
cause serious ramifications, asymptomatic emboli were
counted as a clinical complication. Pulmonary emboli
occurred in 0.6% and 0.01% of augmented vertebrae for
vertebroplasty and kyphoplasty, respectively, while neu-
rologic complications occurred in 0.6% and 0.03% of
vertebrae.
New Fracture Rate After Vertebroplasty
or Kyphoplasty
There were 17 vertebroplasty (n  933 subjects) and 12
kyphoplasty (n  766 subjects) clinical trials that re-
ported new fractures (Figure 5). Of new vertebral frac-
tures using vertebroplasty (n  120 fractures, 12 stud-
ies40,42,44,46–49,69–71,94,95) and kyphoplasty (n  115
fracture, 9 studies41,44,52,54,56,57,83,85,86), 60% and 66%,
respectively, were adjacent to the augmented vertebra.
Unfortunately, follow-up times were not consistent
among studies, and normalization of new fracture rates
by assuming a linear trend is invalid, therefore, making
direct comparisons among studies of differing time lengths
impossible.85 It was noted that both Hillmeier56 and
Kornp58 et al commented on the presence of new fractures
after kyphoplasty, but actual values were unavailable.
Discussion
Our review of literature has identified 69 mainly noncon-
trolled single-group cohort studies. The lack of controls,
methodological flaws, and lack of information concern-
ing patient inclusion criteria and fracture definition pre-
clude definitive conclusions. Despite these limitations,
we have addressed each question outlined in the intro-
duction and provided a critical evaluation of the current
study methodology with future recommendations.
Limitations of This Study
This review does have limitations. Publication bias may
exist by limiting our search to peer-reviewed literature.
The inclusion of low-quality studies may be considered a
limitation of our study methodology. However, the effect
Figure 4. Proportion of vertebrae in which leaks developed during vertebroplasty and kyphoplasty. The body of evidence to date suggests
a high degree of variability in leakage rates for vertebroplasty and kyphoplasty. Differing results may be caused by the amount of cement
injected or percentage of the vertebra filled, level augmented, severity of the fracture, viscosity of the cement, injection pressure, leakage
detection method used, and whether only clinically relevant leaks were reported. Leakage data are presented as the mean 95% CI.
Numbers given below the data points are the mean injected cement volumes (mL).
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of methodological quality was assessed, and no signifi-
cant changes in outcomes were found by removing arti-
cles that scored in the bottom 50%. At this juncture, it
was thought that confounding factors, patient descrip-
tions, inclusion, and counter-indications were lacking
from too many studies to perform a more detailed anal-
ysis. Summary means are a reflection of all studies and, as
such, can be influenced by study or procedural inclusion
criteria. Finally, an article of this scope may be consid-
ered premature, that until randomized, blinded clinical
trials are performed, the use of summarizing results is
questionable. To the contrary, we believe that it is only
by assessing what has been performed and evaluating the
trends that we can determine the need for future research.
Does Vertebroplasty/Kyphoplasty Reduce Patient Pain?
How Does This Compare to Conservative Treatment?
Is Pain Reduction Durable Over the Long-term?
The pain relief experienced by patients appears to be
promising for both kyphoplasty and vertebroplasty in
the short-term (1 year). The majority of patients have
“some pain relief” (Figure 2). Only 2 nonrandomized
prospective studies assessed pain relief obtained after the
procedure compared with conservative treatment.40,41
Augmenting acute painful vertebral fractures, using ver-
tebroplasty, resulted in an immediate (24 hours) decrease
in pain scores (53%) after surgery. After 6 weeks, both
the operated and control groups had a similar clinical
outcome (pain score and physical function). In contrast,
when assessing the outcome of chronic painful vertebral
fractures at 6 months, only the surgical treatment (ky-
phoplasty) resulted in pain relief compared with con-
trols. It is not known what determines whether a subject
will have pain relief. Pain relief is often almost immedi-
ate, but in some patients, especially those who have been
bedridden for longer periods of time, improvements may
be delayed.17,72,105 Long-term follow-up results were
not as frequently reported. However, it appears that pain
relief is durable; little change was noted between postop-
erative scores and long-term results.4
A standard definition of a clinically relevant improve-
ment in pain relief would enhance the comparability,
validity, and applicability of the studies (Figure 2). Suc-
cess should be assessed by the procedure’s ability to pro-
vide clinically meaningful pain relief for the patient. The
effectiveness of the treatment is better reflected in a
change in pain grouping (mild pain [1–4], moderate pain
Figure 5. New fracture rate for vertebral augmentations using vertebroplasty and kyphoplasty. The raw reported number of new fractures
for the 2 procedures is qualitatively similar. Data from the study by Lindsay et al104 has been included, which denotes the incidence rate
of a new vertebral fracture during the first year following a vertebral fracture within a general osteoporotic population. New fracture data
are presented as the mean 95% CI, while follow-up is presented as the mean.
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[5–6], and severe pain [7–10]) than a straight reduction
in pain score.106,107 It is recommended that a reduction
of 33% of the initial preoperative pain score be adopted
as clinically relevant,73,107,108 which will eliminate bias
associated with pretreatment pain level and ensure con-
sistent, relevant reporting. Furthermore, well-designed
studies should be performed to identify patients for
whom vertebroplasty or kyphoplasty presents a clear
benefit, weighed against the risks associated with the
procedure and potential drawbacks of conservative
treatment (e.g., loss of BMD, physical condition).8
What Are the Complications Associated With
the Procedure?
Leakage of the polymethyl methacrylate is the most com-
mon complication and may pose significant physical
danger, even in small quantities.17,67,109 Leakage of un-
reacted monomer, or less likely polymethyl methacrylate
or venography dye, may produce systemic effects result-
ing in toxic reaction or allergic effects leading to acute
arterial hypotension or fever.34,50,74,75,110 Although
there is considerable leakage reported during both pro-
cedures (Figure 4), the actual leakage rate might have
been underreported because of reporting bias or the de-
tection method used.48,111,112 Schmidt et al112 reported
low leakage detection rates and only showed fair inter-
observer reliability using radiographs. Thus, comparing
studies in which leaks were determined by either intra-
operative fluoroscopy or postoperative radiograph could
be confounded by interobserver effects. It is our opinion
that until asymptomatic cement leakage can be disregarded
as irrelevant, the best method to monitor cement leakage,
CT, should be used to report all leaks, not just those
deemed clinically relevant.111,112 The information gained
through the use of postoperative CT must be balanced
against increased patient exposure to radiation and cost.
The majority of clinical complications stem directly
from cement leakage (66% vertebroplasty and 73% ky-
phoplasty). The vast majority of cement leakage is
asymptomatic (96% vertebroplasty and 89% kyphop-
lasty). However, in cases in which cement leakage is im-
mediately clinically asymptomatic, the long-term effect
of these “benign” leaks is unknown. Relatively common
intradiscal leaks may affect the mechanical loading of
either the intravertebral disc or adjacent vertebra. Lin et
al113 reported that 58% of vertebral bodies adjacent to an
intradiscal leak fractured during follow-up compared with
only 12% of vertebral bodies adjacent to augmented verte-
brae in which no intradiscal leakage occurred.
Although they are rare, symptomatic leaks may have
dramatic consequences, such as paraplegia and
death.114–119 Cement leakage into the neural foramen is
often symptomatic, resulting in neurologic complica-
tions.34 Neurologic complications were reported in 7
vertebroplasty10,36,49,68,74,75,102 and 4 kyphoplasty
studies41,55,56,67 described as radiculopathy, a worsening
of pain or spinal compression or injury. Case reports
have documented further major neurologic complica-
tions, including paraparesis, spinal claudication, and
paraplegia, as a result of vertebroplasty.120,121
Cement extravasation into the paravertebral veins
may lead to pulmonary embolism or cardiovascular dis-
tress. There were 7 vertebroplasty4,17,34,37,42,74,75 and 5
kyphoplasty studies8,54,87,88,97 that showed pulmonary
embolism or cardiac complications. Pulmonary emboli
may be a result of cement extravasation or bone marrow
and fat particles that are forced out of the vertebra into
the circulation.122,123 Other instances of pulmonary em-
bolisms, some serious, have been noted in case stud-
ies.124,125 More pulmonary emboli cases may actually
occur than reported because it is not common practice to
perform chest radiographs on asymptomatic patients.
Chest pain felt after vertebroplasty is often attributed to
the procedure but may be caused by embolism. Chest
radiographs taken after the procedure may help in the
early diagnosis of dyspnea.124,125
Higher leakage rates have been reported for single-
group cohort vertebroplasty studies compared to kypho-
plasty studies (Figure 4). The only study that compared
kyphoplasty and vertebroplasty using matched groups
found little difference in leakage rates (28% and 23% of
vertebra had cement leaks for vertebroplasty and kypho-
plasty, respectively).44 It is noteworthy that although ky-
phoplasty leaks were all intradiscal, 4 vertebroplasty
leaks were into the more critical epidural and segmental
vessels regions, although none were symptomatic.44 It
has been hypothesized that higher injection pressures
and lower cement viscosity associated with vertebro-
plasty may create an environment in which leaks are
more likely to occur.52,109
However, in a recent study, no significant difference in
intravertebral pressure was found between vertebroplasty
and kyphoplasty.126 It has been postulated that the creation
of a cavity may decrease leakage risk. It is interesting to note
that those vertebroplasty studies that reduced kyphosis
through patient positioning, and often had associated intra-
vertebral clefts, had lower cement extravasation rates than
the mean (Figure 4). Kim et al76 noted that during cement
filling of vertebrae, which had intravertebral clefts, using
vertebroplasty, the IVC was filled before the surrounding
trabecular bone in a similar manner to that which occurs
during kyphoplasty. Thus, if cement filling is terminated
once the cavity is filled, there may be less chance of cement
extravasation.66
Berlemann et al52 noted that attempting to fill the
vertebra rather than just the cavity produced during ky-
phoplasty resulted in higher leakage rates (33%), more
similar to leakage rates observed during vertebroplasty.
In contrast, Rhyne et al83 only filled the cavity produced
during kyphoplasty and reported a lower leakage rate
(10%). Finally, patient inclusion criteria (fracture sever-
ity definition, vertebra location, and BMD77,78), meth-
odology (leaks determined by CT, radiograph, intraop-
eratively111,112), cement parameters (type, percent fill of
vertebra52,77), and operator experience must be similar
to compare the safety of the 2 procedures, otherwise one
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runs the risk of determining the effect of the confounding
factors rather than the procedures themselves.
Does Vertebroplasty/Kyphoplasty Restore
Patient Function?
Numerous clinically developed but invalidated scales
were used to measure physical function. A standardized
method would make comparison among studies possi-
ble. However, some conclusions can be inferred from the
studies reviewed. The relief from pain does seem to allow
a large majority of patients to increase their physical
function levels. The majority of those patients who had
impairments in function before surgery are able to am-
bulate without assistance after surgery. Improvements in
physical function should only be reported for the subset
of patients who have preoperative impairments. Inclu-
sion of patients who are normal before surgery will not
accurately reflect the efficacy of the intervention to im-
prove physical function because the ratio of impaired
and normal subjects will influence the sensitivity.
Does Vertebroplasty/Kyphoplasty Restore Normal
Spinal Alignment?
Both kyphoplasty and vertebroplasty have the ability to
reduce the kyphotic angle and restore vertebral height
associated with vertebral fractures (Tables 3, 4). Studies
assessing the ability of vertebroplasty to restore height
identified preoperative dynamic mobility as a good indi-
cator of the potential to restore vertebral height.39,92,93
McKiernan et al39 showed that osteoporotic mobile frac-
tures can achieve some height restoration following ver-
tebroplasty, while nonmobile fractures cannot. Carlier et
al92 reported that the postoperative reduction in kypho-
sis angle using vertebroplasty can be predicted from the
preoperative dynamic mobility, something that remains
to be shown for kyphoplasty. Vertebroplasty has no me-
chanical methods to restore vertebral height and relies on
patient positioning or the insertion of bolsters to induce
lordosis, to increase the height of the vertebra and reduce
the kyphotic angle.45,66,67,76,92,93
A majority of the kyphoplasty studies that showed
height restoration were performed on vertebrae with
acute fractures, which had edema present, or were in-
completely healed fractures (Table 3). The presence of
these observations increases the probability that the frac-
ture is mobile. Therefore, kyphoplasty may only be suc-
cessful in restoring height if the fracture is mobile; its
ability to restore vertebral height must be assessed rela-
tive to the spontaneous correction of the patient’s kypho-
sis through positioning alone.127,128 Mobility is mainly
associated with the presence of an intravertebral cleft but
has been observed in cases in which they are not
present.92,129 Carlier et al92 reported significant differ-
ences in height restoration between those subjects in
whom an intravertebral cleft was visible and those in
whom it was not. Thus, studies that show vertebral
height restoration must control for the occurrence of dy-
namic fracture mobility and intravertebral cleft, the pres-
ence of which was only documented for some vertebro-
plasty studies (Table 4).
Of concern is the high percentage of subjects who do
not have any restoration of height following either pro-
cedure. One hypothesis is that height restoration is de-
pendent on the age of the fracture. Berlemann et al52
reported that fracture age was one of the predictors of
fracture correction, a sentiment that was echoed by Lieber-
man et al.97 However, Phillips et al54 found no correlation
between the age of fracture and amount of deformity cor-
rection. Age of the fracture may not be as critical as its
mobility in determining whether a fractured vertebra
has the potential to regain height or reduce kyphosis.
Publishing and interpreting increased vertebral height
must consider confounding factors (the age, severity, and
mobility of the fracture), reporting methodology, and
also the accuracy of the measurement method chosen.
Study results were presented as a percentage reduction of
kyphotic angle or the percentage of height restored,
which may favor severe or mild fractures, depending on
the calculation method chosen.45 The method of report-
ing restoration of height should be standardized in ac-
cordance with the recommendations of McKiernan45
and Teng93 et al to allow direct interstudy comparisons.
Likewise, reporting only the percentage reduction in ky-
photic angle is highly sensitive to the initial kyphotic
angle. The accuracy of the measurement method must be
reported to ensure height restoration exceeds the error.
To be 95% confident that a measured difference in ky-
photic wedge angle represents a true change, the required
difference has been between 3° and 11°.92,127,130,131 In-
traobserver height measurement SD has been between
0.4 and 1.1 mm.129,132
Attention to precision is important in determining the
number of subjects for whom the treatment is effective.
As is evident from Tables 3 and 4, few studies showed the
precision of their methods, and in most, it was not evi-
dent if precision was then used in the analysis of the data.
Patients whose measured results fall below the determine
precision of the measurement method should be consid-
ered as nonresponsive. It was only evident in 3 studies if
any correction for magnification error was performed
(Tables 3, 4). Each radiograph must contain a reference
object that allows the vertebral fracture heights to be
corrected for, or, alternately, the fracture height can be
expressed as a percentage of a reference height (visual-
ized in each radiograph) to negate magnification er-
ror.45,93 Finally, studies must show both height and ky-
phosis reduction. As reported by Kasperk et al,41 it is
entirely possible to have an increase in height and no
reduction in kyphosis angle. Likewise, if only middle
height is reported, it is possible to have no increase in
height but a reduction of kyphosis angle (increase in an-
terior height only).
The whole objective of vertebral height restoration is
to reduce spinal deformity and improve spinal align-
ment. Kyphotic angle is the angle between the superior
and inferior endplates of the fractured vertebra. Unlike
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Cobb angles, which include at least a disc between the
measured endplates, this angle is not influenced by body
position.67,93 As shown in Tables 3 and 4, at least 5
studies used Cobb angle to determine kyphosis angle
reduction. However, it would be useful to have a repeat-
able and sensitive measurement technique that allowed
the overall spinal deformity to be determined.
Does the Incidence of Augmented or Adjacent
Vertebral Fracture Increase After
Vertebroplasty/Kyphoplasty?
It is difficult to determine if the incidence rate of new
fractures increases after vertebroplasty/kyphoplasty be-
cause there is only 1 study41 of limited statistical power
and short follow-up that compares the new vertebral
fracture rate within patients after the procedure com-
pared with a conservative treatment group. Kasperk et
al41 determined that there was no significant difference
between new fracture rates of patients who underwent
kyphoplasty compared to controls (conservative treat-
ment) over a 6-month period. Grohs et al44 reported a
higher incidence of new vertebral fractures for kyphop-
lasty than vertebroplasty. There were 6 (n  35 aug-
mented vertebrae) and 1 (n  29 augmented vertebrae)
new fracture(s) that occurred within 4 months for ky-
phoplasty and vertebroplasty, respectively. Unfortu-
nately, the low study statistical power, lack of fracture
definition, short follow-up, and reporting of only symp-
tomatic fractures (rather than radiologically determined
new fractures) preclude drawing emphatic conclusions.
Additional factors that may confound the results of this
study and others include degree of osteoporosis or spinal
malalignment, patient physical function level, the quan-
tity of cement injected, and intervertebral disc health.
The occurrence of new fractures after the procedure
appears to be nonlinear, with the majority of new frac-
tures occurring within 30 days.71,85 Thus, the linear ex-
trapolation of normalized annual fracture incidence
rates will result in a faulty estimation. The vertebral frac-
ture incidence rate appears to be higher after the proce-
dure than within the general osteoporotic population
that has not had a vertebral fracture develop (cumulative
incidence rate of subjects with a mean age of 74 years is
6.6%), even among those studies that did not attain an
average 1-year follow-up (Figure 5).49,104 However,
whether there is any difference between fracture rates
after the procedure and those within a general osteopo-
rotic population that has had a previous vertebral frac-
ture (19%104) cannot be conclusively ascertained from
the data. The presence of a preexisting fracture has been
reported to increase one’s risk of having a subsequent
vertebral fracture develop by 12.6-fold.133 It is notewor-
thy that two thirds of new fractures reported in studies
included in this review were located adjacent to the aug-
mented vertebra.
Grados75 and Legroux-Ge´rot42 et al calculated the
odds ratio of vertebral fracture in the vicinity of a ce-
mented vertebra to be 2.27 (95% CI 1.11–4.56) and
3.18 (95% CI 0.51–19.64), compared with 1.44 (95%
CI 0.82–2.55) and 2.14 (95% CI 0.17–26.31) for a ver-
tebral fracture in the vicinity of an uncemented fractured
vertebra, respectively. Although this finding may suggest
that the risk of fracture is increased adjacent to an aug-
mented vertebra, it may also be caused by the natural
progression of osteoporosis. A high incidence rate during
the first few months after augmentation, as noted by a
few investigators, may be a result of increased patient
activity levels after the procedure or possible altered
loading, resulting from changes in vertebral geometry or
material behavior.71,85,134,135 The postoperative care re-
ceived by the patients was rarely mentioned in the re-
viewed articles but may play an import role in the new
fracture rate.85 Patients not instructed in proper body
mechanics may be more likely to have a new vertebral
fracture.
The incidence rate of new fractures after vertebro-
plasty/kyphoplasty may be even higher than that re-
ported, depending on the method used to define a new
vertebral fracture. New fractures may result in a poor
outcome after the procedure but not to the extent that
clinical action is required, thereby escaping detection.34
Because it is estimated that only 23% of vertebral frac-
tures are clinical events, long-term follow-up must in-
clude new radiologic analysis and not rely on patients
returning for reevaluation because of recurrent pain.7,104
To ensure that new fractures are properly identified, a
standard definition, such as that proposed by Genant,
must be used.136 Furthermore, fractures that do not re-
quire clinical action can have significant long-term con-
sequences.128
Does Kyphoplasty Offer a Significant Improvement in
Terms of Restoration of Spinal Alignment, Pain
Management, and Reduction in Cement Leakage Over
Traditional Vertebroplasty?
At present, to compare kyphoplasty and vertebroplasty,
it is necessary to use mainly the results of single group
cohort studies, which is far from optimal. Similar results
were noted for pain relief when comparing vertebro-
plasty and kyphoplasty studies. The only study44 that
compares kyphoplasty and vertebroplasty found that
both procedures provided pain relief, but it was more
pronounced for kyphoplasty after 2 years (73% and
41% reduction in VAS, respectively), the reason for
which was not hypothesized. The body of evidence sug-
gests a high degree of variability in the leakage rate for
kyphoplasty and vertebroplasty. Whether the lower
leakage rates are a result of patient inclusion criteria,
creation of a void or trabecular dam (caused by inflation
of the tamp during kyphoplasty), or higher cement vis-
cosity needs to be clarified.48 Height restoration is pos-
sible using kyphoplasty, although it is not effective for all
patients.
However, it has also been noted that similar height
restorations may be possible using vertebroplasty. Grohs
et al44 compared the height restoration of 2 matched
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subject groups for kyphoplasty and vertebroplasty. They
found some height restoration and kyphosis reduction
for kyphoplasty, and none for vertebroplasty. However,
there was no indication that an attempt was made to
reduce the kyphosis for the vertebroplasty group through
the use of patient positioning or bolsters, or if kyphosis
reduction for patients who underwent kyphoplasty
could be achieved by patient positioning alone. It is note-
worthy that intravertebral pseudarthrosis was excluded
from this investigation. Whether kyphoplasty offers a
higher degree of kyphotic angle correction or allows a
higher range of fractures to be treated compared with
vertebroplasty needs to be ascertained. Long-term new
fracture incidence rates appear to be similar for the 2
procedures, but this is based on qualitative examination
of the presented data. The problem with stating conclu-
sively that there is or is not a difference between kypho-
plasty and vertebroplasty outcomes is the lack of com-
parative randomized clinical trials.
Recommendations for the Standardization
of Methodology
Our methodological quality assessment revealed a need
for standardized reporting and methodology, random-
ization, blinding of the patient or the investigator to the
treatment received, reporting the variability of the data,
and the use of a control group. Although it may be im-
practical to blind the patient to the procedure, effective
study design can ensure that in prospective studies, the
investigator is blinded to the patients’ treatment alloca-
tion. Unblinded study designs may result in differential
care bias affecting recorded scores.25 Standardization
would enhance the comparability, validity, and applica-
bility of the studies. To assess reporting quality, we
would encourage investigators to use the checklist pre-
sented in this article (Table 1).
We have outlined in each section methodological rec-
ommendations to ensure that reporting is relevant and
accurate. The methods used to determine the safety and
effectiveness of the procedures should include, as a min-
imum, the following:
● Results should be reported with respect to the frac-
ture pathology.
● Radiologic assessment of fracture severity (using a
method such as that proposed by Grigoryan136 and
Lenchik137 et al) and an estimation of the age of the
fracture should be included.
● Dynamic fracture mobility (supine lateral radio-
graphs compared with standing radiographs)39 and
the presence of intravertebral clefts129,100 must be
noted if reporting height restoration. Height resto-
ration that can be attributed to dynamic mobility
must be corrected for if reporting a mechanical
method of restoring vertebral height.
● Objective outcome measures should be used to as-
sess a reduction in patient pain. VAS (raw values
and the number of patients with clinically relevant
reduction in pain) and a disease-specific functional
outcome such as the ODI or the Osteoporosis Qual-
ity of Life Questionnaire should be included.138
● Physical function should be evaluated using 1 of the
disease-specific function outcomes listed previ-
ously. The improvements should be related to those
with preexisting impairments.
● Cement leakage, assessed by CT, should be docu-
mented.112 Until small leaks can be definitively dis-
counted as having no clinical consequence, all leaks
should be reported.
● Kyphosis reduction and height restoration should
be noted as per the recommendation of McKiernan
et al.45 In addition, height restoration relative to the
initial height lost should be reported in accordance
with the method of Teng et al.93 Adjacent normal
posterior border height should be replaced with the
appropriate reference height on the adjacent verte-
bra (i.e., anterior, middle, or posterior height). Pre-
cision of the radiographic measurement should be
noted and accounted for during analysis. Magnifi-
cation error should be corrected for by standardized
radiograph techniques.45,93 Vertebral wedge angle
should be defined as the angle between the superior
and inferior endplates of the fractured vertebra.76
● Radiographic assessment of new fractures at 3, 6,
and 12 months for all patients should be performed
using a fracture definition, such as that proposed by
Grigoryan et al.136
● All clinical complications should be noted.
The majority of studies included in this review adds to
our preliminary knowledge of the procedures, and offer
insights into their potential benefits and complications.
However, many questions still remain unanswered. They
include but are not constrained to: Why does pain relief
occur? How can cement leaks be avoided? Are asymp-
tomatic leaks clinically relevant? How do clinical results
of vertebroplasty differ from kyphoplasty? What inclu-
sion criteria ensure that pain relief or kyphosis reduction
is possible? Can new fractures be prevented (are they a
result of the procedures or a natural progression of os-
teoporosis)? To facilitate the comparison of future stud-
ies, the adoption of a standardized reporting method
would be highly beneficial. With the assistance of the
recommendations proposed, it is now time to proceed to
the next step with well-controlled clinical trials.
Key Points
● Some pain relief was reported for 92% and 87%
of kyphoplasty and vertebroplasty procedures, re-
spectively.
● Leakage rates were higher for vertebroplasty
(41%) than kyphoplasty (9%).
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● Height restoration is possible using kyphoplasty
and for a subset of patients with mobile fractures
using vertebroplasty. However, 34% and 39% of
kyphoplasty and vertebroplasty (with mobile frac-
ture) procedures, respectively, do not result in any
height restoration.
● New fractures of adjacent vertebrae occurred af-
ter both procedures. Whether this is caused by al-
tered loading, increased patient activity, or the nat-
ural progression of osteoporosis has yet to be
determined.
● The adoption of standardized reporting and
methodology, and an increase in methodological
quality would enhance comparability, validity, and
applicability of the studies.
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